This clinical trial is focused on studying the long-term safety of the medication nivolumab, either used alone or in combination with other cancer treatments. The study is designed for patients who have previously participated in trials sponsored by BMS, a pharmaceutical company, and are dealing with various types of cancer, collectively referred to as pan tumor. The main goal is to ensure that the treatments continue to be safe for patients over an extended period.
Participants in this study will continue to receive their cancer treatment as they did in their previous trial, which may include nivolumab or other therapies. The study will monitor the occurrence of any side effects, including those that might lead to stopping the treatment, serious side effects, and immune-related side effects. The study will also track the overall survival of participants, which means observing how long patients live after starting the treatment in the study.
The study will run until 2030, allowing researchers to gather comprehensive data on the long-term effects of these cancer treatments. This information will help in understanding the safety and effectiveness of nivolumab and its combinations with other therapies for patients with different types of cancer. Participants will be required to follow the treatment schedule and attend regular check-ups to ensure their safety and the collection of accurate data.
Austria 
Belgium 
Czechia 
France 
Germany 
Greece 
Italy 
Poland 
Romania 
Spain 